Emerging Markets Regulatory Tracker: China (Vol. 4 No. 21)
This article was originally published in PharmAsia News
Executive Summary
China needs to reform its drug registration system through capacity building along with provincial review procedures, according to China FDA Deputy Director Wu Zhen.